-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Leap Therapeutics announced that its investigational inhibitor DKN-01, which targets a new target DKK1, as a single agent or in combination with paclitaxel, has achieved positive results in a Phase 2 "basket trial" for the treatment of advanced gynecological cancers.
DKN-01 is a humanized monoclonal antibody that can block its activity by binding to the DKK1 protein.
In this basket trial of 111 patients with different types of advanced gynecological cancer, patients with epithelial endometrial cancer (EEC), epithelial ovarian cancer (EOC) and carcinosarcoma (MMMT) received DKN-01 monotherapy or DKN- 01/Treatment of paclitaxel combination therapy.
DKN-01 shows stronger anticancer activity in patients whose tumors highly express DKK1.
Among 24 patients receiving DKN-01/paclitaxel combination therapy, the PFS of patients with high DKK1 expression was 5.
"In this study, DKN-01 resulted in objective remission, including a patient who received monotherapy and had sustained complete remission for up to two and a half years.
Reference materials:
[1] Leap Therapeutics Presents DKN-01 Clinical Data at theSociety of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer.
